
    
      Primary Endpoint(s): Change in Y-BOCS score from baseline to endpoint at weeks 12 and 24;
      and, number (and percent) "responders" at weeks 12 and 24, defined as subjects with a 35%
      decrease in Y-BOCS score at endpoint and a Clinical Global Impressions score of 1 or 2 (very
      much or much improved).

      Secondary Endpoint(s):

        1. change in scores on the Work and Social Adjustment Scale, a quality of life measure

        2. change in scores on the Work Productivity and Activity Impairment

           Questionnaire:

           Specific Health Problem scale; in particular, we will analyze change in work hours/week
           lost because of OCD, and change in effect of OCD on work productivity (0-10 scale).

        3. dollar cost per responder

        4. dollar cost per total number of patients needed to produce one additional responder in
           the Luvox-CR plus web-based CBT group over the number produced by Luvox-CR alone, i.e.,
           dollar cost per number needed to treat

        5. dollar cost per 5% decrease in Y-BOCS score at weeks 12 and 24 in the two treatment
           groups.
    
  